Abstract:ATPase family AAA domain-containing protein 2 (ATAD2), a chromatin regulator and an oncogenic transcription cofactor, is frequently overexpressed in many cancers, particularly in hepatocellular carcinoma (HCC). By integrating open-access online mRNA datasets and our institutional tissue data on HCC, the clinical role and functions of ATAD2 were analyzed by bioinformatic algorithms. We systematically examined ATAD2 expression in HCC based on a large sample population, integrating data from our institution and the GEO, Oncomine, and TCGA datasets. Aberrant ATAD2 expression related to pathways was identified by bioinformatic algorithms. The effects of ATAD2 downregulation on the cycle cell were also determined. A pooled analysis from 28 datasets indicated that ATAD2 overexpression was found in HCC ( SMD = 8.88 , 95% CI: 5.96–11.81, P < 0.001 ) and was correlated with poor survival. Subgroup analysis of Asian patients with a serum alpha-fetoprotein (AFP) concentration < 200 ng/ml in stage I + II showed that the ATAD2-high group had a more unfavorable overall survival (OS) rate than the ATAD2-low group. The receiver operating characteristic curve indicated that the efficiency of ATAD2 for HCC diagnosis was considerable ( area under the curve = 0.89 , 95% CI: 0.86–0.91). Functional analysis based on bioinformatic algorithms demonstrated that ATAD2 participates in cell division, mitotic nuclear division, DNA replication, repair, and cell cycle processes. ATAD2 knockout in HCC cells downregulated cyclin C and cyclin D1 protein levels and resulted in G1/S phase arrest in vitro. The kinesin family member C1 (KIFC1), shugoshin 1 (SGO1), GINS complex subunit 1 (GINS1), and TPX2 microtubule nucleation factor (TPX2) genes were closely related to ATAD2 upregulation. ATAD2 may interact with TTK protein kinase (TTK) to accelerate HCC carcinogenesis. ATAD2 plays a vital role in HCC carcinogenesis by disturbing the interaction between chromatin proteins and DNA. Targeting ATAD2 represents a promising method for the development of therapeutic treatments for cancer.

ATAD2 and TWIST1 Interaction Promotes MYC Activation in Colorectal Carcinoma

Tumor-Promoting ATAD2 and Its Preclinical Challenges

AKT-ions with a TWIST between EMT and MET.

Targeting Bromodomain Protein ANCCA/ATAD2 Enhances the Efficacy of DNA‑damaging Chemotherapy Agents and Radiation.

ATAD2 drives colorectal cancer progression by regulating TRIM25 expression via a positive feedback loop with E2F transcriptional factors

Atad2 Overexpression Identifies Colorectal Cancer Patients With Poor Prognosis And Drives Proliferation Of Cancer Cells

ATAD2 Promotes Glycolysis and Tumor Progression in Clear Cell Renal Cell Carcinoma by Regulating the Transcriptional Activity of C-Myc

Both Tead-Binding and Ww Domains Are Required for the Growth Stimulation and Oncogenic Transformation Activity of Yes-Associated Protein

Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma

Pan-cancer analysis of the immunological and oncogenic roles of ATAD2 with verification in papillary thyroid carcinoma

Regulation of P21 by TWIST2 Contributes to Its Tumor-Suppressor Function in Human Acute Myeloid Leukemia.

The Aurora-A-Twist1 Axis Promotes Highly Aggressive Phenotypes in Pancreatic Carcinoma.

TWIST1 and Cancer

Data from Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem–like Cell Traits in Breast Cancer

Twist: a Molecular Target in Cancer Therapeutics

TWIST1-EP300 Expedites Gastric Cancer Cell Resistance to Apatinib by Activating the Expression of COL1A2

Twist Mediates an Aggressive Phenotype in Human Colorectal Cancer Cells.

ATAD2 controls chromatin-bound HIRA turnover

Overexpression of ATAD2 Indicates Poor Prognosis in Oral Squamous Cell Carcinoma.

ATAD2 in Cancer: a Pharmacologically Challenging but Tractable Target

KAT2A succinyltransferase activity-mediated 14-3-3ζ upregulation promotes β-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells.